Skip to main content
Jyong Biotech Ltd. logo

Jyong Biotech Ltd. — Investor Relations & Filings

Ticker · MENS ISIN · KYG831161065 US Manufacturing
Open in API
Filings indexed 64 across all filing types
Latest filing 2026-05-14 Annual Report
Country US United States of America
Listing US MENS

About Jyong Biotech Ltd.

https://jyongbio.com/

Jyong Biotech Ltd. is a science-driven biotechnology company focused on the development and commercialization of plant-derived drugs for urinary system diseases. The company's primary therapeutic areas include benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Its lead drug candidate, MCS-2, is a botanical formulation that has completed late-stage (Phase III) clinical trials. Leveraging a proprietary research and development platform, Jyong Biotech aims to advance its pipeline of innovative botanical medicines to address unmet medical needs in urology for a global patient population.

Recent filings

Filing Released Lang Actions
ANNUAL REPORT
Annual Report FY 2025
2026-05-14 English
6-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 6-K filed with the SEC, which is a report of a foreign private issuer. The content announces a change in senior management, specifically the appointment of a new Chief Financial Officer replacing the previous one. The document is short (2023 characters) and focuses solely on management change without financial data or other report content. According to the definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG).
2026-02-06 English
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025. The document explicitly states it is furnishing interim financial data and includes balance sheets and statements of operations. The length is 2186 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR) rather than a report publication announcement or regulatory filing. The presence of unaudited interim financial statements confirms this classification.
2026-01-09 English
SP 15D2
Annual Report Classification · 100% confidence The document is a Form 20-F filed with the SEC, which is an annual report for foreign private issuers. It covers the fiscal year ended December 31, 2024, and includes detailed audited consolidated financial statements, auditor's report, and notes. The presence of the auditor's opinion, comprehensive financial statements, and the SEC form type clearly indicate this is a full annual report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the filing type corresponds to an Annual Report (10-K equivalent for foreign issuers).
2025-06-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It details the entry into a material definitive agreement related to an underwriting agreement for an initial public offering (IPO) of the company's shares. The document includes information about the offering, the underwriting agreement, and related press releases. It does not contain comprehensive financial statements or detailed financial performance data, but rather an update on a capital raising event. This fits the definition of a Capital/Financing Update (CAP). The document length is 4969 characters, which is sufficient to contain substantive information about the financing event, not just an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2025-06-18 English
PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for an initial public offering (IPO) of ordinary shares by Jyong Biotech Ltd. It includes information about the offering price, underwriting, company structure, risk factors, and regulatory compliance. The presence of the term 'prospectus' and the detailed offering information indicates this is a capital raising document. It is not an annual report, earnings release, or any other type of financial report but specifically a document related to capital issuance and financing. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is the actual prospectus, not just an announcement of it.
2025-06-18 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.